Navigation Links
ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12
Date:9/6/2011

SAN DIEGO, Sept. 6, 2011 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Rodman & Renshaw Annual Global Investment Conference on Monday September 12, 2011 at 2:25 p.m. Eastern time, in the Metropolitan East Salon at the Waldorf=Astoria Hotel in New York.

Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals web site at www.adventrx.com. An archived presentation will be available on the web site for 30 days.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company focused on developing proprietary product candidates.  The Company's current lead product candidates are ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis, and ANX-514, a detergent-free reformulation of the blockbuster drug Taxotere®, which recently went off-patent.  The Company is evaluating its Exelbine program following the complete response letter it received from the FDA.  More information can be found on the Company's web site at www.adventrx.com.  


'/>"/>
SOURCE ADVENTRX Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. ADVENTRX Provides Update on All Three Pipeline Products
2. ADVENTRX Reports Second Quarter 2011 Financial Results
3. ADVENTRX Pharmaceuticals to Present at the 31st Annual Canaccord Genuity Growth Conference on August 11
4. Vista Partners Initiates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $7.50
5. ADVENTRX Reports First Quarter 2011 Financial Results
6. ADVENTRX Completes Acquisition of SynthRx
7. ADVENTRX Pharmaceuticals Provides Update on ANX-514
8. ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc.
9. ADVENTRX to Provide Update Regarding Pipeline Expansion Efforts
10. ADVENTRX Pharmaceuticals to Present at the 13th Annual BIOCEO & Investor Conference on February 15
11. ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance in ... medical-grade battery-powered display stand specifically designed for endoscopy environments. An innovative ... into a clinical solution to support the improvement of patient outcomes, ... Design ... Solution ...
(Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
(Date:10/4/2017)... 4, 2017 OBP Medical , ... medical devices, today announced regulatory approval from ... (or Agência Nacional de Vigilância Sanitária (ANVISA)) to ... surgical retractor with integrated LED light source and ... and exposure of a tissue pocket or cavity ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
Breaking Medicine News(10 mins):